IL17A and psoriasis: Secukinumab is a human monoclonal IgG1 k antibody that was developed to block the actions of IL-17A.6, 7, 8, 9 In 2015, an anti-IL-17 was approved for the first time, for the treatment of moderate-to-severe psoriasis and psoriatic arthritis in adult patients.10